“It also has the potential to modify quality metrics that are currently monitored and reported whether in the actual outcome measures or in the patient group in which these metrics are applied to,” Lam said.
While the joint organizations agree on the ACP’s call for individualized therapy, their chief concern comes from their “lumping together most diabetes patients,” Clinical Affairs Core Committee Chair Grazia Aleppo, MD, told MD Magazine.
Aleppo noted the ACP guidelines do not give consideration to promising clinical data from intensive blood glucose control trials, nor the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists. The latter 2 therapies’ clinical efficacy in reducing the morbidity and mortality of high-risk patients with T2D is counterintuitive to the lax guidelines, Aleppo said.
“In the primary care setting — or even the endocrinologist setting — not every patient with T2D has the advanced form of the disease,” Aleppo said. “Why not keep these people in the best A1C condition possible?”